Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
Nicolas Girard, MD
Conference Coverage
Subcutaneous Amivantamab Plus Lazertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/18/2025
Nicolas Girard, MD
Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Nicolas Girard, MD, discusses...
09/18/2025
Oncology
Conference Coverage
Success Rate of NGS Panel in Cytology and Needle Core Biopsy Samples
09/09/2025
Allison Casey
A next-generation sequencing panel for cytology and needle core biopsy samples was able to meet the clinical molecular oncology need, compared to that of surgical resection samples.
A next-generation sequencing panel for cytology and needle core biopsy samples was able to meet the clinical molecular oncology need, compared to that of surgical resection samples.
A next-generation sequencing...
09/09/2025
Oncology
Conference Coverage
Overexpression of HER2 Among Patients With Non-Small Cell Lung Cancer
09/09/2025
Allison Casey
Overexpression of HER2 in both cytology and surgical pathology specimens can be used to identify those patients with NSCLC who would benefit from HER2-targeted therapies.
Overexpression of HER2 in both cytology and surgical pathology specimens can be used to identify those patients with NSCLC who would benefit from HER2-targeted therapies.
Overexpression of HER2 in both...
09/09/2025
Oncology
Conference Coverage
Fine-Needle Aspiration vs Surgical Pathology Specimens for PD-L1 Expression Evaluation
09/09/2025
Allison Casey
According to a quality assurance project, there was moderate concordance between cytology and surgical specimens when evaluating PD-L1 expression.
According to a quality assurance project, there was moderate concordance between cytology and surgical specimens when evaluating PD-L1 expression.
According to a quality assurance...
09/09/2025
Oncology
Conference Coverage
Concurrent Durvalumab With Chemoradiotherapy Did Not Improve Outcomes Among Patients With Unresectable Stage III NSCLC
09/08/2025
Allison Casey
Starting durvalumab concurrent with chemoradiotherapy and continuing as consolidation did not improve OS for patients with unresectable stage III non-small cell lung cancer.
Starting durvalumab concurrent with chemoradiotherapy and continuing as consolidation did not improve OS for patients with unresectable stage III non-small cell lung cancer.
Starting durvalumab concurrent...
09/08/2025
Oncology
Conference Coverage
Zidesamtinib for Patients With ROS1-Positive Advanced NSCLC
09/08/2025
Allison Casey
Zidesamtinib showed clinically meaningful activity and durability among patients with advanced ROS1-positive non-small cell lung cancer.
Zidesamtinib showed clinically meaningful activity and durability among patients with advanced ROS1-positive non-small cell lung cancer.
Zidesamtinib showed clinically...
09/08/2025
Oncology
Conference Coverage
Aumolertinib Plus Chemotherapy for Advanced NSCLC With EGFR and Tumor Suppression Gene Mutations
09/08/2025
Allison Casey
According to the phase 3 ACROSS study, aumolertinib plus chemotherapy improved progression-free survival among patients with advanced non-small cell lung cancer harboring EGFR sensitizing mutations with tumor suppression gene mutations.
According to the phase 3 ACROSS study, aumolertinib plus chemotherapy improved progression-free survival among patients with advanced non-small cell lung cancer harboring EGFR sensitizing mutations with tumor suppression gene mutations.
According to the phase 3 ACROSS...
09/08/2025
Oncology
Conference Coverage
Osimertinib Plus Chemotherapy as First-Line Standard-of-Care for Advanced EGFR-Mutant Non-Small Cell Lung Cancer
09/08/2025
Allison Casey
According to the phase 3 FLAURA2 study, osimertinib plus chemotherapy showed a statistically significant and clinically meaningful improvement to overall survival among patients with EGFR-mutant advanced non-small cell lung cancer.
According to the phase 3 FLAURA2 study, osimertinib plus chemotherapy showed a statistically significant and clinically meaningful improvement to overall survival among patients with EGFR-mutant advanced non-small cell lung cancer.
According to the phase 3 FLAURA2...
09/08/2025
Oncology
Conference Coverage
TROP2 Evaluation by Quantitative Continuous Scoring Among Patients With Non-Small Cell Lung Cancer
09/05/2025
Allison Casey
TROP2 evaluation among patients with NSCLC by quantitative continuous scoring was found to be reproducible across pathologists and serves as a robust approach for the real-world setting.
TROP2 evaluation among patients with NSCLC by quantitative continuous scoring was found to be reproducible across pathologists and serves as a robust approach for the real-world setting.
TROP2 evaluation among patients...
09/05/2025
Oncology
Conference Coverage
MET Positivity Not Predictive of Response to Amivantamab-Based Therapy Among Patients With EGFR-Mutant Lung Cancer
09/02/2025
Allison Casey
MET positivity was not validated as a biomarker for response to treatment with amivantamab-based treatment among patients with EGFR-mutant non-small cell lung cancer.
MET positivity was not validated as a biomarker for response to treatment with amivantamab-based treatment among patients with EGFR-mutant non-small cell lung cancer.
MET positivity was not validated...
09/02/2025
Oncology
Conference Coverage
Novel Whole Genome Sequencing Assay Demonstrates Promise in Detecting Ultrasensitive MRD Among Patients With Early-Stage Non-Small Cell Lung Cancer
09/02/2025
Stephanie Holland
Study results demonstrated that the use of a novel whole genome sequencing tumor-informed assay provided greater ultrasensitive molecular residual disease detection compared to historical controls with a first-generation assay among patients...
Study results demonstrated that the use of a novel whole genome sequencing tumor-informed assay provided greater ultrasensitive molecular residual disease detection compared to historical controls with a first-generation assay among patients...
Study results demonstrated that...
09/02/2025
Oncology

News

Nicolas Girard, MD
Conference Coverage
Subcutaneous Amivantamab Plus Lazertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/18/2025
Nicolas Girard, MD
Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Nicolas Girard, MD, discusses...
09/18/2025
Oncology
Conference Coverage
Success Rate of NGS Panel in Cytology and Needle Core Biopsy Samples
09/09/2025
Allison Casey
A next-generation sequencing panel for cytology and needle core biopsy samples was able to meet the clinical molecular oncology need, compared to that of surgical resection samples.
A next-generation sequencing panel for cytology and needle core biopsy samples was able to meet the clinical molecular oncology need, compared to that of surgical resection samples.
A next-generation sequencing...
09/09/2025
Oncology
Conference Coverage
Overexpression of HER2 Among Patients With Non-Small Cell Lung Cancer
09/09/2025
Allison Casey
Overexpression of HER2 in both cytology and surgical pathology specimens can be used to identify those patients with NSCLC who would benefit from HER2-targeted therapies.
Overexpression of HER2 in both cytology and surgical pathology specimens can be used to identify those patients with NSCLC who would benefit from HER2-targeted therapies.
Overexpression of HER2 in both...
09/09/2025
Oncology
Conference Coverage
Fine-Needle Aspiration vs Surgical Pathology Specimens for PD-L1 Expression Evaluation
09/09/2025
Allison Casey
According to a quality assurance project, there was moderate concordance between cytology and surgical specimens when evaluating PD-L1 expression.
According to a quality assurance project, there was moderate concordance between cytology and surgical specimens when evaluating PD-L1 expression.
According to a quality assurance...
09/09/2025
Oncology
Conference Coverage
Concurrent Durvalumab With Chemoradiotherapy Did Not Improve Outcomes Among Patients With Unresectable Stage III NSCLC
09/08/2025
Allison Casey
Starting durvalumab concurrent with chemoradiotherapy and continuing as consolidation did not improve OS for patients with unresectable stage III non-small cell lung cancer.
Starting durvalumab concurrent with chemoradiotherapy and continuing as consolidation did not improve OS for patients with unresectable stage III non-small cell lung cancer.
Starting durvalumab concurrent...
09/08/2025
Oncology
Conference Coverage
Zidesamtinib for Patients With ROS1-Positive Advanced NSCLC
09/08/2025
Allison Casey
Zidesamtinib showed clinically meaningful activity and durability among patients with advanced ROS1-positive non-small cell lung cancer.
Zidesamtinib showed clinically meaningful activity and durability among patients with advanced ROS1-positive non-small cell lung cancer.
Zidesamtinib showed clinically...
09/08/2025
Oncology
Conference Coverage
Aumolertinib Plus Chemotherapy for Advanced NSCLC With EGFR and Tumor Suppression Gene Mutations
09/08/2025
Allison Casey
According to the phase 3 ACROSS study, aumolertinib plus chemotherapy improved progression-free survival among patients with advanced non-small cell lung cancer harboring EGFR sensitizing mutations with tumor suppression gene mutations.
According to the phase 3 ACROSS study, aumolertinib plus chemotherapy improved progression-free survival among patients with advanced non-small cell lung cancer harboring EGFR sensitizing mutations with tumor suppression gene mutations.
According to the phase 3 ACROSS...
09/08/2025
Oncology
Conference Coverage
Osimertinib Plus Chemotherapy as First-Line Standard-of-Care for Advanced EGFR-Mutant Non-Small Cell Lung Cancer
09/08/2025
Allison Casey
According to the phase 3 FLAURA2 study, osimertinib plus chemotherapy showed a statistically significant and clinically meaningful improvement to overall survival among patients with EGFR-mutant advanced non-small cell lung cancer.
According to the phase 3 FLAURA2 study, osimertinib plus chemotherapy showed a statistically significant and clinically meaningful improvement to overall survival among patients with EGFR-mutant advanced non-small cell lung cancer.
According to the phase 3 FLAURA2...
09/08/2025
Oncology
Conference Coverage
TROP2 Evaluation by Quantitative Continuous Scoring Among Patients With Non-Small Cell Lung Cancer
09/05/2025
Allison Casey
TROP2 evaluation among patients with NSCLC by quantitative continuous scoring was found to be reproducible across pathologists and serves as a robust approach for the real-world setting.
TROP2 evaluation among patients with NSCLC by quantitative continuous scoring was found to be reproducible across pathologists and serves as a robust approach for the real-world setting.
TROP2 evaluation among patients...
09/05/2025
Oncology
Conference Coverage
MET Positivity Not Predictive of Response to Amivantamab-Based Therapy Among Patients With EGFR-Mutant Lung Cancer
09/02/2025
Allison Casey
MET positivity was not validated as a biomarker for response to treatment with amivantamab-based treatment among patients with EGFR-mutant non-small cell lung cancer.
MET positivity was not validated as a biomarker for response to treatment with amivantamab-based treatment among patients with EGFR-mutant non-small cell lung cancer.
MET positivity was not validated...
09/02/2025
Oncology

Interactive Features

Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Recent News

News
Afatinib Plus Carboplatin and Pemetrexed Demonstrates Efficacy, Safety Among Patients WIth Advanced EGFR-Mutated Non-Small Cell Lung Cancer
08/27/2025
Stephanie Holland
According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...
According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...
According to results from the...
08/27/2025
Oncology
FDA Approval
FDA Approves Zongertinib for Non-Squamous Non-Small Cell Lung Cancer With HER2 Tyrosine Kinase Domain Activating Mutations
08/12/2025
Stephanie Holland
Based on results from the Beamion LUNG-1 trial, the US FDA has approved zongertinib for previously treated patients with unresectable or metastatic non-squamous non-small cell lung cancer with HER2 tyrosine kinase domain activating mutations.
Based on results from the Beamion LUNG-1 trial, the US FDA has approved zongertinib for previously treated patients with unresectable or metastatic non-squamous non-small cell lung cancer with HER2 tyrosine kinase domain activating mutations.
Based on results from the...
08/12/2025
Oncology
News
Patritumab Deruxtecan Demonstrates Clinical Promise Among Patients With Advanced Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations
08/08/2025
Stephanie Holland
According to results from cohort 2 of the phase 1 U31402-A-U102 trial, HER3-DXd demonstrated promising efficacy and safety among previously treated patients with advanced non-small cell lung cancer harboring uncommon EGFR mutations.
According to results from cohort 2 of the phase 1 U31402-A-U102 trial, HER3-DXd demonstrated promising efficacy and safety among previously treated patients with advanced non-small cell lung cancer harboring uncommon EGFR mutations.
According to results from cohort...
08/08/2025
Oncology
News
Potential Therapeutic Targets for Patients With Invasive Mucinous Adenocarcinoma
07/24/2025
Allison Casey
A recent study found invasive mucinous adenocarcinomas have a higher likelihood of harboring KRAS mutations and NRG fusion genes.
A recent study found invasive mucinous adenocarcinomas have a higher likelihood of harboring KRAS mutations and NRG fusion genes.
A recent study found invasive...
07/24/2025
Oncology
News
Neoadjuvant Nivolumab Plus Chemotherapy Improves Survival for Patients With Resectable Non-Small Cell Lung Cancer
07/10/2025
Stephanie Holland
Updated results from the phase 3 CheckMate 816 trial demonstrated that neoadjuvant nivolumab plus chemotherapy significantly improved survival compared to chemotherapy alone among patients with resectable non-small cell lung cancer.
Updated results from the phase 3 CheckMate 816 trial demonstrated that neoadjuvant nivolumab plus chemotherapy significantly improved survival compared to chemotherapy alone among patients with resectable non-small cell lung cancer.
Updated results from the phase 3...
07/10/2025
Oncology
FDA Approval
FDA Approves Sunvozertinib for EGFR Exon 20-Mutated Metastatic Non-Small Cell Lung Cancer
07/02/2025
Janelle Bradley
On July 2, 2025, the FDA granted accelerated approval to sunvozertinib for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.
On July 2, 2025, the FDA granted accelerated approval to sunvozertinib for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.
On July 2, 2025, the FDA granted...
07/02/2025
Oncology
News
First-Line Sugemalimab Plus Chemotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
06/30/2025
Stephanie Holland
According to updated results from the phase 3 GEMSTONE-302 trial, sugemalimab plus platinum-based chemotherapy demonstrated long-term efficacy and safety among patients with metastatic non-small cell lung cancer.
According to updated results from the phase 3 GEMSTONE-302 trial, sugemalimab plus platinum-based chemotherapy demonstrated long-term efficacy and safety among patients with metastatic non-small cell lung cancer.
According to updated results...
06/30/2025
Oncology
Conference Coverage
Sosimerasib for Patients With Locally Advanced or Metastatic KRAS G12C-Mutated Non-Small Cell Lung Cancer
06/25/2025
Stephanie Holland
According to results from a phase 2 study, sosimerasib demonstrated promise among patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.
According to results from a phase 2 study, sosimerasib demonstrated promise among patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.
According to results from a...
06/25/2025
Oncology
FDA Approval
FDA Approves Datopotamab Deruxtecan for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
06/23/2025
Stephanie Holland
Based on pooled subgroup results from the TROPION-Lung 05 and TROPION-Lung 01 trials, the FDA has approved datopotamab deruxtecan for previously treated patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Based on pooled subgroup results from the TROPION-Lung 05 and TROPION-Lung 01 trials, the FDA has approved datopotamab deruxtecan for previously treated patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Based on pooled subgroup results...
06/23/2025
Oncology
Conference Coverage
Datopotamab Deruxtecan Plus Pembrolizumab With and Without Platinum-Based Chemotherapy Demonstrates Promise in Advanced Non-Small Cell Lung Cancer
06/18/2025
Stephanie Holland
According to results from the TROPION-Lung02 study, datopotamab deruxtecan plus pembrolizumab both with and without the addition of platinum-based chemotherapy demonstrated promising durability and safety among patients with advanced...
According to results from the TROPION-Lung02 study, datopotamab deruxtecan plus pembrolizumab both with and without the addition of platinum-based chemotherapy demonstrated promising durability and safety among patients with advanced...
According to results from the...
06/18/2025
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use